Human Cytomegalovirus Immunoglobulin
For more information about CMV Immunoglobulin-VF, please visit the
Australian Red Cross Blood Servicewebsite
NHMRC website to obtain the Immunisation handbook
CMV Immunoglobulin-VF is a preparation of human immunoglobulin for intravenous administration. The letters CMV stand for cytomegalovirus, a type of virus.
CMV Immunoglobulin-VF is prepared from blood obtained from voluntary and non-remunerated (unpaid) donors. Donations used to make CMV Immunoglobulin-VF are selected on the basis that they contain high levels of antibodies specific to cytomegalovirus. CMV Immunoglobulin-VF contains antibodies which can provide protection against cytomegalovirus infection in some transplant patients. It may also help in the treatment of cytomegalovirus infection.
CMV Immunoglobulin-VF is available only with a doctor’s prescription.
Who is this information for?
This information is relevant in Australia and is intended for health care professionals or people who have been prescribed this product.
Consumer Medicine Information
The Consumer Medicine Information is a leaflet written for people who have been prescribed CMV Immunoglobulin-VF, and contains information about the medicine including:
- What CMV Immunoglobulin-VF is used for
- How CMV Immunoglobulin-VF works
- How CMV Immunoglobulin-VF is given
- Side effects
- Further Information
CMV Immunoglobulin-VF Consumer Medicine Information (PDF, 0.035MB)
Product Information contains information to ensure the safe and effective use of a medicine. This document is approved by the Therapeutic Goods Administration and made available by CSL for you if you are a:
- qualified healthcare professional; or
- consumer, provided you have read the Consumer Medicine Information for the product; want further information on the product; and agree to consult with your healthcare professional if you have any questions in relation to the Product Information.
CMV Immunoglobulin-VF Product Information (PDF, 0.07MB)® Registered Trademark of CSL Limited
Last Updated: 30/12/2012